Defi Pharmaceutical Ecosystem
V.01.02
November 5th 2020
Market Understanding:
The global pharmaceutical market has experienced significant growth in recent years. As of end-2019, the total global pharmaceutical market was valued at about 1.25 trillion U.S. dollars. This is a significant increase from 2001 when the market was valued at just 390 billion U.S. dollars. The pharmaceutical market plays a key role in how people get medications and what people pay for medication. However, some markets are better for pharmaceutical companies than others. Globally, the United States has emerged as the leading market for pharmaceuticals, followed by the group of emerging markets. Emerging markets can include middle and low-income countries such as Brazil, India, Russia, Colombia and Egypt, to name a few. Despite increasing revenues globally, the Latin American region accounts for the lowest share of the global pharmaceutical market’s revenues.
The top pharmaceutical products sold globally include Humira, Eliquis and Revlimid. Many of these pharmaceuticals are approved to treat multiple chronic conditions or cancers. Oncologic is the top therapeutic class for drug sales globally, followed by antidiabetics. However, the sales of drugs for autoimmune diseases and diabetes has experienced some of the largest growth in spending in recent years.
Market Analysis and Prediction are the main required tools to evaluate pharmaceutical markets, and the role of decentralized platforms is crucial to know better about:
- Market Understanding
- Brand/Generic evaluation
- New launch product plan
- Smart Investment plan
- Smart Supply chain plan
- Patient access to healthcare systems.
Introduction
Pharmalyse Finance provides future-proof blockchain and AI (Artificial Intelligence) based provenance systems for the pharmaceutical and healthcare sector. Pharmalyse Finance digital solutions and services create efficiencies, accountability and transparency for supply chains, ease the burden of compliance requirements, reduce costs and eliminate counterfeit or substandard products.
The DeFi Pharmalyse.Finance platform, is developing the DeFi Blockchain, a blockchain specifically dedicated to decentralized pharmaceutical prediction. By focusing on the functionality of the blockchain and dedicating it specifically to predict, Analyze and forecast pharmaceutical sales opportunity worldwide, PLF solutions create immutable and incorruptible records to ensure data integrity and full auditability.
This means our data analytics and AI services can be trusted. PLF DeFi Blockchain ecosystem provides unparalleled high transaction throughput, reduced risk of errors, correct IMS data entry, and intelligent feature development specifically for the fulfillment of financial services on the pharmaceutical blockchain.
Problems & Solutions
Today, almost all pharmaceutical financial data, Analysis, opportunity and risks are run by pharmaceutical companies and governments. Investors use local data of drug sales to put their money into interest or dividend-making instruments in order to grow their wealth regardless R&D investments, local capacity, Infra structures and Financial backgrounds The problems with financial services are increasingly becoming obvious to everyone: compounded costs due to middle government/company, slow transactions, delays to access data, and inaccessibility to many sectors of the population. A myriad of transparent solutions have been brought in to improve the system, but fundamentally the underlying government system which shows local opportunities.
Today Patients access to fair health care system and medicines is one of the important issues which need more organized platform on decentralized ecosystem, means health accessible to all. Patients access to novel medicines and healthcare system which is the main vision of Pharmalyse Finance now
PLF Decentralized Finance (DeFi) offer a way to start with a new system, circumventing the difficulties faced in changing the finance in pharma industry. Investors can easily evaluate
pharmaceutical potentials risk and opportunities, import and export
Pharmalyse Finance Defi ecosystem shows growth rate of companies in different sectors also real transparent potential of therapeutic areas.
PLF Defi helps patients to find required drug on blockchain supply guide worldwide
Out of Stock situation and segmentation based on geographical supply.
Focus on Enhancing the Pharmaceutical Supply Chain
Given the ability of blockchain technology to enable secure and rapid transactions around the world, much of the efforts in the pharmaceutical industry to leverage its capabilities are focused around improving the supply chain.
One of the biggest benefits of PLF Decentralized platform is the ability to create an auditable trail and establish drug provenance across the entire
supply chain as nearly 70% of pharmaceutical and life science leaders believe blockchain will have the greatest impact in this area.
With PLF decentralized blockchain solution, both manufacturers and their clients would be able to independently verify the quality and point of origin of drugs quickly and securely.
Transparency and security are two other key benefits of blockchain technology for members of the pharmaceutical supply chain. All of the stakeholders involved in the supply chain must be able to share and update data while also being assured the data is timely and accurate. With PLF technology, the entire supply chain can be
managed with one piece of software that is shared between authorized stakeholders. In addition to drug manufacturers and their suppliers, payers, providers, pharmacies, and patients can access the data and see when it is updated in near real time.
With Pharmalyse Finance, these issues can be avoided because the entire supply chain can be managed with one piece of software that is shared between authorized stakeholders. In addition to drug manufacturers and their suppliers, payers, providers, pharmacies, and patients can access the data and see when it is updated in near real-time.
Blockchain technology also has the potential to help prevent diversion, counterfeiting and tampering, because drug products can be tracked from the time they are produced until the time they reach patients. Any attempts to change records will be visible to all parties immediately.
As importantly, recalls are much simpler. The product can be readily traced back to the manufacturer and associated with a
production batch, allowing identification of other potentially problematic products and where they had been shipped.
Market Analysis and Prediction
Defi ecosystem in Pharmaceutical sectors: Analysis & Prediction
§ Smart Decision on market potentials:
Borders and regulations silo all the centralized prediction markets. The problem here is that the strength of a prediction market is directly proportional to size of disease and patient flow. The more operators and regulators you have, the more you limit access to the markets, reducing its effectiveness. PLF decentralized platform makes collective prediction regarding smart objectives of pharmaceutical companies in terms of:
Number of patients
Incidence of disease
Physician’s prescription behaviors
Pharmaceutical Strategy Making:
The DeFi Pharmalyse Finance platform, is developing the DeFi Blockchain, a blockchain specifically dedicated to decentralized pharmaceutical prediction and market analysis (PLF.M) By focusing on the functionality of the blockchain and dedicating it specifically to predict , Analyze and forecast pharmaceutical sales opportunity worldwide, the DeFi Blockchain provides unparalleled high transaction throughput, reduced risk of errors, correct IMS data entry, and intelligent feature development specifically for the fulfillment of financial services on the pharmaceutical blockchain.
Patients: PALFIN Make health accessible to all.
PATIENTS: Wisdom of crowds is the idea that large groups of patients can collectively make smarter decisions than individuals. This is the core concept behind decentralized Pharmalyse Finance
PALF Token bypasses intermediaries:
Being an intermediary, Pharmaceutical markets usually charge trading fees and take cuts from company`s profits. If you are a regular user, then all these fees tend to add up and PLF is a rapid pathway with no extra fee
Pharmalyse Finance in pharmaceutical R&D
More than any other industry, the pharmaceutical sector is highly dependent on research and development, with some companies investing around 20 percent of their sales revenues in R&D projects. This share can be much higher at companies that specialize in research and generate low sales. The discovery of new drugs is vital for the continued growth of pharma companies, and sales of new branded drugs can provide sizeable contributions to total revenues. However, the loss of patent protection can have serious consequences, and competition from generic drugs is a major challenge for companies. The expiration of a product patent can result in a significant reduction in revenues, as experienced by Pfizer’s Lipitor from 2012 onwards.
With increasing demand for quality healthcare solutions, the pharmaceutical industry is evolving rampantly since past few decades. Highly efficient medicines and other treatment based solutions are responsible for pushing various markets operating in this sector. PLF Defi Ecosystem offers further fields for application along the pharmaceutical value chain. Pharmaceutical R&D is a major source of information asymmetry between firms and investors and among investors themselves. Information asymmetry captures the problem that firms internally know more about their strengths and values than outside investors on the capital markets.
The R&D progress is a complex procedure, making it difficult for investors to derive information:
1st , the absence of reliable information creates uncertainty with investors and asymmetric information, which complicates valuation.
2nd, many R&D projects are unique to the developing firm with little comparability across companies for the.
3rd, there are no tradable markets for R&D.
4th, reporting rules treat R&D differently from other investments.
R&D expenditures are usually expensed immediately, even under international accounting standards. PLF allows for a capitalization of intangibles if there is a substantial probability of future benefits. The drug development process is characterized by a high degree of uncertainty and, thus, pharmaceutical companies often are unlikely to qualify for that regulation. Other investments are capitalized and impaired in subsequent periods. Hence, investors obtain beliefs of the management about any value change of the asset, which they in turn can incorporate into their valuation.
An immediate expense of R&D deprives that information from the investors. Consequently, information asymmetry between managers and outside investors likely arises. Information asymmetry is apparent in various industries, but it is arguably strongest in companies in the pharmaceutical sector and a potential driver of abnormal returns of up to 4- 6% annually. In the early research phase, funding from investors is critical for successful drug development. Abnormal returns may adversely affect funding.
One potential opportunity to increase information access to investors in the early research phase, while at the same time keeping track of ownership of proprietary information, could be the management of the early innovation process via the blockchain. Trust and integrity between several stakeholders, such as research companies and investors, is established through active collaboration and clever coding.
Pharmalyse Finance will increase effectiveness and transparency in the early research phase. PLF blockchain ensures information exchange and flow across different processes of the innovation stage. Transaction costs occurred by contractual issues related to confidentiality would be minimized. In real time, information is visible to the regulator and funding parties, reducing information asymmetry and potentially reducing abnormal returns.
PALF token will also enable the implementation of virtual trials, in which there is no centralized trial center and patients receive their medications and have samples picked up at home. Such trials make it possible for patients in remote locations or who have difficulty traveling due to complications of their diseases to participate. They also eliminate the need for extensive physical facilities and a large staff. The success of virtual trials, however, depends largely on the ability to collect and securely maintain data.
Supply
An initial supply of 2,750 PALFIN tokens is to be minted by the deployer.
The majority of the initial supply will be locked into Defi Pharmaceutical Ecosystem V.1.02 Uniswap along with a proposed amount of 20 ETH contributed by the community during a pre-sale event to provide initial liquidity.
The presale token price is 1 ETH = 50 PALFIN (capped at 1.0 ETH per investor).
1,000 PALF + 20 ETH to be deposited into Uniswap for initial liquidity.
1,000 PALF will be sent to the seed investors.
The remaining amount (750 PALF) will be distributed as follows:
250 PALF (9 %) → Airdrop
200 PALF (7 %) → treasury fund,
200 PALF (7 %) → community & marketing fund,
100 PALF (3.5 %) → development team,
Mint rate: 75 PALF per day (0,0125 PALF per block) → 25,0 % emissions cut every 2 weeks (starting 01.11.2020)
Burn rate:
2 % on every transfer → raised to 3 % on 12.12.2020 Developer rate: 3.5 % on every block -Transfers to/from master contract address are exempt from this to allow people to stake/unstake PALFIN tokens without losing out on burn amounts. -We might change this rate to 35 % or 20 % depending on the current market conditions. The emission rates are not finalized and are a topic that we will put our community on to decide.
Our emission cut rates will be carried out so many times until the emission rate will be at approximately the same level as the (future) burn rate. This means we will closely monitor the network activity and carry out necessary adjustments if needed.
MINT — BURN RATE EQUILIBRIUM
Our end goal is to reach an equilibrium between the currently burned amount of tokens per day and the minted amount of tokens per day. This will require us to be closely monitoring the network activity and to make adjustments when necessary. An initial 3,0 % burn rate on every transfer will be deployed along with the minting contract. The burn rate can be changed by a community vote.
DEVELOPER RATE
An initial 4,0 % developer rate on every block will be deployed along with the minting contract. After the token has had time to grow and the community surrounding it becomes more mature, the developer rate could be changed by a community vote after the ownership of the master contract is transferred to a governance contract.
